| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c17fccde78a87242732508161966f51 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-122 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-66 |
| filingDate |
2004-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_656462afb672b596ba3aa847467890ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd2e8849a90ec5fa10e70696b2fceaee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afd456b215ec3101d1db9069a8f67d40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f0278a5bbac18376fea52d2aa6af54a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8553237081498e5cbf94d1ef2b23591a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98cc0a629e2afb806db76f8b9afaa684
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ec65d44e05ba379a228a73d5c763c1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1b818f8f9197ca932cbaa0b69b3c91d |
| publicationDate |
2009-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2353350-C2 |
| titleOfInvention |
Advanced drug delivery system |
| abstract |
FIELD: medicine. n SUBSTANCE: invention refers to chemical-pharmaceutical industry, and concerns an oral drug delivery system including biliquid foam containing continuous hydrophilic phase 1 to 20 wt %, pharmaceutically acceptable oil 70 to 98 wt % producing discontinuous phase. A slightly water-soluble drug 0.1 to 20 wt % is dissolved or dispersed in said pharmaceutically acceptable oil. The drug delivery system also contains biliquid foam with included surface-active substance 0.5 to 10 wt % to produce stable biliquid foam with all the amounts specified in percentage of total composition. n EFFECT: drug delivery system ensures high bioavailability of slightly water-soluble oral drugs. n 22 cl, 16 ex, 1 tbl |
| priorityDate |
2003-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |